Vistagen Therapeutics, Inc. (VTGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vistagen Therapeutics, Inc. on September 15, 2025, covering events occurring on September 9 and September 10, 2025. The report details the resignation of the Chief Financial Officer and the results of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and personnel changes rather than financial performance data.
Material Changes and Corporate Events
- Executive Departure: Cynthia L. Anderson, Chief Financial Officer and principal financial and accounting officer, resigned effective October 15, 2025. The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Transition Plan: The Company is searching for a successor and intends to enter into a consulting services agreement with Ms. Anderson to support the transition.
- Annual Meeting Results: On September 9, 2025, stockholders voted on three proposals:
| Proposal | Outcome | Key Vote Counts |
|---|---|---|
| Election of Directors | All 6 nominees elected | Votes ranged from 12.2M to 12.4M "For" |
| Say-on-Pay (Advisory) | Approved | 11.48M For, 299k Against, 1.02M Abstain |
| Ratification of Auditors (KPMG LLP) | Ratified | 21.17M For, 346k Against, 55k Abstain |
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the search for a CFO successor and the execution of a consulting agreement. Management notes that these statements involve risks and uncertainties, including those detailed in the Company's Form 10-K for the fiscal year ended March 31, 2025, and Form 10-Q for the period ended June 30, 2025. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the timeline for the appointment of a new Chief Financial Officer.
- Review the terms of the proposed consulting services agreement with the departing CFO.
- Confirm the Company's cash position and runway in light of the leadership transition.
- Examine the definitive proxy statement filed on July 28, 2025, for detailed executive compensation data.